The Democratic Republic of the Congo has enrolled more than 25 patients in a clinical trial testing an oral medicine designed to prevent Ebola infection in high-risk contacts, marking an aggressive push to contain what the World Health Organization calls the largest outbreak on record in the country. The trial, led by the DRC's National Institute for Biomedical Research alongside international partners, administers the experimental prophylaxis for 10 days to confirmed contacts of Ebola patients to determine whether it can block disease onset.
As of August 1, the outbreak had claimed 1,657 lives among 3,748 recorded cases, with 708 recoveries documented. The speed of the response reflects lessons learned from previous outbreaks—protocols were written before the outbreak was declared in mid-May, allowing trials to launch faster than in past crises. Yet the race against time remains urgent. Vasee Moorthy, acting lead of WHO's R&D Blueprint, acknowledged that definitive conclusions from ongoing trials would likely take several months.
The Challenge of Speed and Safety
Expanding trial enrollment requires balancing rapid response with rigorous safety monitoring. Dr. Moorthy emphasized that clinical trials demand careful oversight of enrolled patients, which necessarily slows enrollment even as the outbreak accelerates. "We are trying to ramp up the enrolment," he said. "Because they're a clinical trial, we have to have safe, monitoring of the people that are enrolled in the trial. And that does take time to have more and more teams and more sites enrolling."
To address this constraint, the response has expanded infrastructure. A new 100-bed treatment center opened in Bunia, the capital of Ituri province, where the outbreak is concentrated. Three testing sites now operate across Ituri, with a fourth scheduled to open within days. These facilities allow patients to enroll in trials and receive monitoring in controlled conditions—a prerequisite for determining whether medicines actually work.
Vaccine Development Racing Forward
Parallel to the prophylaxis trial, development of the first Bundibugyo species-specific vaccine has accelerated. Candidate vaccine trials began in the United Kingdom on July 24, with a second trial launching in Canada this week. Both trials are being conducted on ferrets and monkeys before WHO's technical advisory group analyzes results and decides whether to advance to subsequent phases.
The WHO emphasized a critical reality: there are still no proven safe and efficacious treatment, preventive, or vaccination options for the Bundibugyo species of Ebola virus. Results may be months away. Meanwhile, the agency's technical advisory group convened last Friday to review new animal study data on Ervebo, an existing vaccine targeting a different Ebola strain, with recommendations expected this week.
International Support and Border Response
The UN's response spans multiple agencies coordinating resources and logistics. The UN refugee agency (UNHCR) supports screening, infection prevention, and hygiene provision. At the DRC-Uganda border, a mobile laboratory backed by WHO and the World Food Programme delivers Ebola test results within one hour—a critical improvement that brings diagnostics closer to more than 94,000 people in border regions. UNICEF operates nurseries for children from Ebola-affected families, addressing secondary impacts of the outbreak.
The MONUSCO peacekeeping mission protects civilians, conducts community information campaigns, and has increased presence around medical facilities to support WHO teams. The UN's Office for the Coordination of Humanitarian Affairs (OCHA) is releasing up to $60 million through the Global Emergency Fund (CERF) to support response and preparedness efforts in the DRC and neighboring countries.
Why This Matters:
The DRC's outbreak presents a test of whether rapid clinical trial protocols and coordinated international response can contain a pathogen with no existing proven treatments or vaccines. The fiscal commitment—$60 million in emergency funding alone—reflects the scale of the crisis and the costs of delayed action. The expansion of testing sites and treatment infrastructure demonstrates how outbreak response requires sustained investment in medical facilities and personnel. Success or failure in this trial will determine whether oral prophylaxis becomes a viable tool for future outbreaks, potentially reducing reliance on reactive containment measures. The speed at which protocols were prepared before the outbreak was declared suggests that institutional preparation matters—advance planning enabled faster action than previous crises allowed. For policymakers, the trial underscores both the importance of investing in biomedical research infrastructure and the reality that even with accelerated timelines, definitive answers take months, not weeks.